Urology News and Research

Latest Urology News and Research

Study reveals potential marker for prostate cancer

Studies by a Purdue University-led team have revealed a potential marker for prostate cancer that could be the starting point for less invasive testing and improved diagnosis of the disease.

3 Aug 2010

ARO uses Elekta VMAT system for prostate cancer patients

In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."

From Elekta 2 Aug 2010

Processed meats may increase risk of developing bladder cancer: Research

A new study suggests that consuming specific compounds in meat related to processing methods may be associated with an increased risk of developing bladder cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may be relevant for understanding the role of dietary exposures in cancer risk.

2 Aug 2010

Warner Chilcott announces $2.25 billion of new debt to fund special dividend

Warner Chilcott plc today announced a recapitalization pursuant to which it intends to incur, subject to market and other conditions, $2.25 billion of new debt to fund a special dividend to Warner Chilcott's ordinary shareholders of $8.50 per share, or approximately $2.15 billion in the aggregate. The new debt is expected to be comprised of a combination of senior secured term loans and additional unsecured debt.

31 Jul 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

Surgeons continue to advance minimally-invasive surgery for kidney cancer patients

Surgeons at the University of California, San Diego School of Medicine continue to advance minimally-invasive surgery for cancer patients by reducing the number of abdominal incisions from approximately six to a single small incision.

30 Jul 2010

Actient Pharmaceuticals completes transaction to license, acquire pharmaceutical products from UCB

GTCR, one of the country's leading private equity firms, announced today that Actient Pharmaceuticals, LLC has successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an international biopharmaceutical company based in Brussels, Belgium.

30 Jul 2010

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Medtronic, Inc. today announced the global launch of the Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial. It is the industry's first prospective, randomized study evaluating the clinical feasibility of spinal cord stimulation, or neurostimulation, to improve clinical signs and symptoms of heart failure.

30 Jul 2010

NeoGenomics second-quarter 2010 revenue increases 14% to $8.5 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2010.

29 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

NeoTract selects SYSPRO ERP

SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that NeoTract, Inc., a Medical Device start-up company headquartered in Pleasanton, Calif., has selected SYSPRO ERP (Enterprise Resource Planning) software to manage the company's financial, manufacturing and distribution operations.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Scientists develop new surgical procedure for prostate cancer using natural orifices

With a recent first of its kind surgery, physicians at Mayo Clinic in Arizona have developed a new surgical procedure for the treatment of prostate cancer using natural orifices - signaling the next step in the evolution of minimally invasive surgery.

29 Jul 2010

Bioniche, Synerx announce FDA approval and launch of Isosulfan Blue Injection 1%

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.

29 Jul 2010

Aggressive prostate cancer patients tend to retain denser bones

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.

29 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Regeneron Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates.

28 Jul 2010

Cancer survivor to celebrate 100th birthday

Loyola University Hospital cancer patient Mary Cipolla was 89 years old when she underwent one of the most extensive operations in surgery, known as the Whipple procedure.

28 Jul 2010

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Antares Pharma, Inc. announced today positive results from its Phase 3 study of Anturol Gel in patients with overactive bladder. The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied.

28 Jul 2010

Urology News and Research

Latest Urology News and Research

Study reveals potential marker for prostate cancer

ARO uses Elekta VMAT system for prostate cancer patients

Processed meats may increase risk of developing bladder cancer: Research

Warner Chilcott announces $2.25 billion of new debt to fund special dividend

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Surgeons continue to advance minimally-invasive surgery for kidney cancer patients

Actient Pharmaceuticals completes transaction to license, acquire pharmaceutical products from UCB

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

NeoGenomics second-quarter 2010 revenue increases 14% to $8.5 million

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

NeoTract selects SYSPRO ERP

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Scientists develop new surgical procedure for prostate cancer using natural orifices

Bioniche, Synerx announce FDA approval and launch of Isosulfan Blue Injection 1%

Aggressive prostate cancer patients tend to retain denser bones

Allos reports net loss of $20.0 million for second-quarter 2010

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Cancer survivor to celebrate 100th birthday

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Urology News and Research

Latest Urology News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in